CStone Pharmaceuticals Enters Exclusive Commercialization Partnership with Istituto Gentili for Sugemalimab in Western Europe and the UK
July 8, 2025 – CStone Pharmaceuticals (Stock Code: 2616.HK), an innovative biopharmaceutical company focused on anti-tumor drug research and development, announced that it has reached an exclusive strategic cooperation with Istituto Gentili ("Gentili"), a century-old oncology biopharmaceutical company with deep roots in the European market, regarding the commercialization of sugemalimab in Western Europe and the UK.
more